Lei Lei Wu is a news reporter for Endpoints News, specializing in reporting on drugs and biotechs. With a focus on the pharmaceutical industry, Lei Lei covers topics such as clinical trial results, FDA approvals, and biotech company developments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Lei Lei Wu's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly on biotechnology, pharmaceutical companies, gene therapy, clinical trials, and drug development. The majority of her articles are based on press releases and cite data.
Given this focus, she would likely be interested in receiving pitches related to new developments in biotechnology or pharmaceuticals backed by solid data or press releases. Pitches offering insights from experts within these fields regarding groundbreaking studies or significant advancements in drug development may resonate with her. Additionally, providing access to exclusive data or early access to important press releases could enhance the effectiveness of outreach efforts.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Eli Lilly announced Tuesday that its diabetes and weight loss drug tirzepatide succeeded in a Phase II study for MASH, or metabolic dysfunction-associated steatohepatitis.
Over a decade ago, a group of researchers led by two diabetes experts, Richard DiMarchi and Matthias Tschöp, published a landmark paper in mice that suggested a new way to treat obesity and diabetes. The drug in the study activated two gut hormone receptors — the now famous GLP-1 and
By: Lei Lei Wu
Corner Therapeutics' $54 million Series A will be used to bring new immunotherapies for cancer and infectious diseases into the clinic, the company said Thursday. The startup is led by Steve Altschuler, who co-founded Spark Therapeutics and was previously CEO of the Children’s Hospital of Philadelphia. Altschuler serves as the
By: Lei Lei Wu
A new biotech is coming out of stealth with $16 million to develop cell therapies for solid cancers — an area where scientists have had limited success. OverT Bio (pronounced
By: Gene Tx
BALTIMORE — Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday.
By: Lei Lei Wu
An experimental prostate cancer drug developed by Johnson & Johnson that uses a rare radioactive particle called actinium-225 led to three patients seeing their tumors shrink substantially, but four patient deaths, according to the first results from an early-stage study. The therapy resulted in five cases of interstitial lung disease,
Gilead on Thursday disclosed that Trodelvy, the antibody-drug conjugate that is a key part of the drugmaker's oncology business, failed a Phase 3 study after …
By: Lei Lei Wu
Researchers from MIT and Harvard have crafted a new tool to silence genes without editing their sequence and are using it to develop a treatment for prion disease, a fatal neurodegenerative condition caused by misfolded proteins. Led by Sonia Vallabh of the Broad Institute and Jonathan Weissman of MIT’s Whitehead
By: Lei Lei Wu
The advent of new targeted oncology therapies may benefit more than just cancer patients. Two patients with severe arteriovenous malformations — an ultra-rare condition where a group of blood vessels forms incorrectly — saw their symptoms improve substantially after taking Lumakras, a pill developed by Amgen for cancers driven by
Intellia Therapeutics' CRISPR-based treatment for a rare genetic disease called hereditary angioedema reduced the bouts of swelling associated with the disease in a mid-stage test …
(833) 317-6278 
